Project Grant R43DA058470
- The U.S. National Institute on Drug Abuse (NIDA) awarded Altrumed LLC a $404,078 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a device-agnostic hypoxia detection software for opioid overdose prediction and positive reversal monitoring. The project, titled "DEVICE-AGNOSTIC HYPOXIA DETECTION SOFTWARE FOR OVERDOSE PREDICTION AND POSITIVE REVERSAL MONITORING," aims to create an innovative wearable sensor system that integrates advanced...
- The National Science Foundation (NSF) awarded a Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Resilient Lifescience, Inc. for the development and validation of a novel wearable medical device to detect and treat opioid overdose. The $274,964 award, effective March 15, 2024 through December 31, 2024, will fund the development of two key components: 1) a self-contained, patch-based drug delivery platform capable of reliably delivering multiple...
- This Project Grant, awarded by the National Institute on Drug Abuse (NIDA), will fund research to develop an advanced optical device that can quantify cerebral oxygenation and blood flow in infants with prenatal opioid exposure. The $251,006 award will support a 2-year study (7/15/2025 - 6/30/2027) to acquire longitudinal data on cerebral physiology in the first week of life for this population and evaluate associations with short-term clinical outcomes. The proposed hybrid device that...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a software-based medical device (SAMD) for detecting opioid use through voice analysis. The $800,000 award to Tenvos Inc., a minority-owned and woman-owned technology company, aims to advance the company's AI-driven solution that can enable patients to remotely test for opioid use and securely share results with...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,715.00 to Rescue Biomedical, LLC to develop and commercialize the Automatic Detection Device (AD2) component of their Automatic Antidote Delivery Device (A2D2). The AD2 is a user-centric wearable device that aims to automatically detect opioid overdose and respiratory depression, with the goal of reducing the need for intensive...
- This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
- This federal Project Grant award from the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to develop a wireless bioelectronic system for high-performance fentanyl monitoring in the brains of freely moving small animal models. The $358,371 award, effective from October 1, 2025 to September 30, 2028, will support three key objectives: Isolating, characterizing, and engineering aptamers (targeting molecules) for the primary opioid fentanyl associated with opioid use...
- This federal Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program provides $649,585 to Auburn University to develop an integrated and miniaturized opioid sensor system. The project aims to address the opioid crisis through innovative, cost-efficient, and portable opioid biosensors that can enable real-time, accurate detection and monitoring. The interdisciplinary team is working to deliver solutions for law...
- This Project Grant award of $371,021 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a continuous respiratory monitoring platform to better classify apnea of prematurity (AOP) in premature newborns. The primary products to be delivered are: 1) a multimodal system and machine learning model to accurately detect and classify the major types of AOP (central, obstructive, and mixed); and 2) an optimized prototype system...
- This Cooperative Agreement award of $1,278,689 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop an automated Neonatal Pain Monitoring System (NPMS) and pain management protocol to objectively measure and minimize postoperative pain in newborns. The project has two key objectives: 1) Develop and validate AI-driven neonatal pain biomarker signatures and an automated NPMS to continuously...
NONCONTACT REMOTE MONITORING FOR THE DETECTION OF OPIOID-INDUCED RESPIRATORY DEPRESSION - THE US OPIOID CRISIS CONTINUES TO HAVE A CATASTROPHIC IMPACT ON HUMAN LIVES AND THE ONGOING COVID-19 PANDEMIC IS COMPOUNDING ITS EFFECTS. BASED ON THE STATISTICS PUBLISHED BY THE CDC, 91,799 DRUG OVERDOSE DEATHS OCCURRED IN THE US IN 2020, WHERE THE AGE-ADJUSTED OVERDOSE DEATHS INCREASED BY 31% FROM 2019 TO 2020. IN ADDITION, OPIOIDS, WHICH CAUSE RESPIRATORY DEPRESSION, WERE INVOLVED IN 75% OF ALL DRUG OVERDOSE DEATHS IN THE US. WE PROPOSE TO BUILD ON OUR WORK IN NON-INVASIVE MONITORING OF VITAL SIGNS TO DEVELOP AN FDA- REGULATED MEDICAL DEVICE WITH A PRIMARY APPLICATION IN MONITORING PATIENTS FOR OPIOID-INDUCED RESPIRATORY DEPRESSION. THIS INCLUDES AT-HOME MONITORING OF PATIENTS WITH CHRONIC PAIN BEING TREATED WITH HIGH-DOSE OPIOID PRESCRIPTION MEDICATIONS OR PATIENTS SUFFERING FROM OPIOID USE DISORDER (OUD) AS WELL AS MONITORING SUBJECTS WITH OUD AT SUPERVISED INJECTION SITES (ALSO KNOWN AS SUPERVISED CONSUMPTION SPACES). OUR OVERALL GOAL IS TO DEVELOP A NON-CONTACT MULTI-MODAL MONITORING SYSTEM FOR THE DETECTION OF OPIOID-INDUCED RESPIRATORY DEPRESSION AT HOME AND IN SUPERVISED INJECTION SITES. WHILE RADAR IS CAPABLE OF PENETRATING THROUGH CLOTHING AND BLANKETS TO MEASURE CHEST WALL MOVEMENTS RESULTING FROM RESPIRATION, IT REQUIRES THE GUIDANCE OF DEPTH IMAGING TO TARGET A PERSON AND THE CHEST AREA. OUR SPECIFIC AIMS ARE: 1. ESTIMATE TIDAL VOLUME USING A NONCONTACT MONITORING SYSTEM. OUR CURRENT TECHNOLOGY IS CAPABLE OF DETECTING RESPIRATORY RATE WITH A HIGH DEGREE OF ACCURACY FOR STATIONARY SUBJECTS. HOWEVER, ROBUST DETECTION OF RESPIRATORY DEPRESSION INVOLVES MONITORING OF RESPIRATORY RATE, PATTERN, AND DEPTH (I.E., TIDAL VOLUME). AS PART OF THIS SPECIFIC AIM, WE WILL DEVELOP A FRAMEWORK TO ESTIMATE TIDAL VOLUME OF A STATIONARY SUBJECT USING RADAR AND DEPTH INFORMATION, WHERE WE ESTIMATE TIDAL VOLUME FROM CHEST WALL DISPLACEMENTS. FURTHERMORE, WE WILL EXTRACT FEATURES TO CHARACTERIZE RESPIRATORY PATTERN FROM THE ACQUIRED RADAR SIGNAL. AS A PRIMARY VALIDATION OF THIS ESTIMATION FRAMEWORK, OUR SYSTEM WILL BE TESTED ON 20 HEALTHY VOLUNTEERS. THE OUTCOME OF THE TEST WILL PROVIDE US WITH PRELIMINARY DATA REGARDING THE ACCURACY OF THE RADAR AND THE DEPTH-BASED TIDAL VOLUME ESTIMATION AS COMPARED WITH THE GOLD STANDARD. 2. DEVELOP AND VALIDATE A FRAMEWORK FOR INTEGRATING DATA FROM SENSORS TO DETECT RESPIRATORY DEPRESSION. IN THIS SPECIFIC AIM, WE WILL DEVELOP A FRAMEWORK TO USE THE RESPIRATORY RATE, RESPIRATORY PATTERN, AND TIDAL VOLUME INFORMATION FROM THE RADAR AND DEPTH CAMERA TO DETERMINE IF RESPIRATORY DEPRESSION HAS OCCURRED. THIS INVOLVES A TWO-STEP APPROACH, WHERE WE EXTRACT RESPIRATORY FEATURES TO CHARACTERIZE RESPIRATORY PATTERNS TO COMPLEMENT RESPIRATORY RATE AND TIDAL VOLUME, AND THEN USE A MACHINE LEARNING MODEL TO DETECT THE OCCURRENCE OF RESPIRATORY DEPRESSION. TO HELP WITH DESIGN THE RIGHT MODEL, WE WILL COLLECT DATA USING OUR RADAR AND DEPTH IMAGING SYSTEM FROM ANESTHETIZED PIGS GOING THROUGH OPIOID-INDUCED RESPIRATORY DEPRESSION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/24/25 | ||
| Not listed | $0 | 4/3/24 | ||
| Not listed | $55.0k | 4/2/24 | ||
| Not listed | $325.0k | 6/8/23 | ||
| Not listed | $325.0k | 6/8/23 |